RNA 针对小分子药物研发市场－全球产业规模、份额、趋势、机会及预测（按适应症、最终用户、地区和竞争细分，2020-2030 年）

2024 年全球 RNA 标靶小分子药物发现市值为 16.8 亿美元，预计到 2030 年将达到 55.2 亿美元，复合年增长率为 21.93%。这种增长是由对 RNA 靶向小分子药物不断增长的需求所推动的，这些药物能够治疗多种疾病，包括癌症、神经系统疾病和遗传疾病。 RNA 标靶药物研发方法的创新和政府对 RNA 研究的加强支持正在加速该领域的发展，吸引了整个製药业的大量投资和兴趣。

关键市场驱动因素

RNA生物学和药物发现技术的进展

主要市场挑战

RNA结构的复杂性与标靶特异性

主要市场趋势

人工智慧在药物研发的应用

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球RNA标靶小分子药物研发市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依适应症（癌症、传染病、代谢性疾病、神经系统疾病、其他）
  • 按最终用户（製药和生物製药公司、学术和研究机构等）
  • 按地区（北美、欧洲、亚太、南美、中东和非洲）
  • 按公司分类（2024）
• 市场地图
• 按适应症
• 按最终用户
• 按地区

第六章：北美RNA标靶小分子药物研发市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲RNA标靶小分子药物研发市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区RNA标靶小分子药物研发市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：南美RNA标靶小分子药物研发市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第十章：中东与非洲RNA标靶小分子药物研发市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 近期发展
• 併购
• 产品发布

第十三章：全球RNA标靶小分子药物研发市场：SWOT分析

第 14 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 15 章：竞争格局

• Accent Therapeutics, Inc.
• Anima Biotech Inc.
• Arrakis Therapeutics, Inc.
• AstraZeneca Plc
• Epics Therapeutics, Inc.
• Expansion Therapeutics, Inc.
• F.Hoffmann-La Roche AG
• H3 Biomedicine Inc.
• PTC Therapeutics, Inc.
• Ribometrix, Inc.

第 16 章：策略建议

第17章调查会社について・免责事项

The Global RNA Targeting Small Molecule Drug Discovery Market, valued at USD 1.68 billion in 2024, is projected to reach USD 5.52 billion by 2030, growing at a CAGR of 21.93%. This growth is fueled by the increasing demand for RNA-targeted small molecule drugs capable of addressing a wide range of conditions, including cancer, neurological, and genetic disorders. Innovations in RNA-targeted drug discovery methods and heightened government support for RNA research are accelerating development in this field, attracting significant investments and interest across the pharmaceutical industry.

Key Market Drivers

Advancements in RNA Biology and Drug Discovery Technologies

Recent developments in RNA biology have revealed new RNA structures and functionalities as viable therapeutic targets. Tools like high-throughput sequencing and gene editing have significantly advanced the discovery of novel RNA targets and the creation of small molecules that can regulate RNA activity. These technological strides are streamlining drug development, making therapies more precise and effective. Moreover, the integration of computational methods and artificial intelligence is improving the prediction of RNA structures and interactions, thereby enhancing the efficiency of the discovery process. These advancements are driving increased pharmaceutical investment in RNA-targeted therapy.

Key Market Challenges

Complexity of RNA Structures and Target Specificity

Designing small molecules to selectively bind RNA targets is inherently challenging due to the intricate secondary and tertiary structures of RNA molecules. Precision is vital to prevent unintended interactions with non-target RNAs, which could cause adverse effects. The flexible nature of RNA adds another layer of difficulty in identifying stable and effective binding sites. Overcoming these hurdles necessitates sophisticated structural analysis tools and innovative drug development strategies, which demand substantial time and resources.

Key Market Trends

Integration of Artificial Intelligence in Drug Discovery

Artificial Intelligence (AI) is playing a transformative role in the discovery of RNA-targeted small molecules. AI technologies are capable of analyzing large datasets to forecast RNA structures, locate potential binding regions, and simulate molecular behavior, which greatly accelerates candidate identification. This not only improves the precision and efficiency of development but also cuts down the time and expense compared to traditional methods. As AI tools continue to evolve, their contribution to RNA-based therapeutic discovery is expected to grow, paving new pathways for drug development.

Key Market Players

• Accent Therapeutics, Inc.
• Anima Biotech Inc.
• Arrakis Therapeutics, Inc.
• AstraZeneca Plc
• Epics Therapeutics, Inc.
• Expansion Therapeutics, Inc.
• F. Hoffmann-La Roche AG
• H3 Biomedicine Inc.
• PTC Therapeutics, Inc.
• Ribometrix, Inc.

Report Scope:

In this report, Global RNA Targeting Small Molecule Drug Discovery market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

RNA Targeting Small Molecule Drug Discovery Market, By Indication:

• Cancer
• Infectious Diseases
• Metabolic Diseases
• Neurological Diseases
• Other

RNA Targeting Small Molecule Drug Discovery Market, By End Users:

• Pharmaceutical and Biopharmaceutical Companies
• Academic and Research Institutes
• Others

RNA Targeting Small Molecule Drug Discovery Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global RNA Targeting Small Molecule Drug Discovery Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global RNA Targeting Small Molecule Drug Discovery Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)
  • 5.2.2. By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)
  • 5.2.3. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
  • 5.2.4. By Company (2024)
• 5.3. Market Map
• 5.3.1 By Indication
• 5.3.2 By End Users
• 5.3.3 By Region

6. North America RNA Targeting Small Molecule Drug Discovery Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)
  • 6.2.2. By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Indication
      • 6.3.1.2.2. By End User
  • 6.3.2. Canada RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Indication
      • 6.3.2.2.2. By End User
  • 6.3.3. Mexico RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Indication
      • 6.3.3.2.2. By End User

7. Europe RNA Targeting Small Molecule Drug Discovery Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)
  • 7.2.2. By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Indication
      • 7.3.1.2.2. By End User
  • 7.3.2. Germany RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Indication
      • 7.3.2.2.2. By End User
  • 7.3.3. United Kingdom RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Indication
      • 7.3.3.2.2. By End User
  • 7.3.4. Italy RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Indication
      • 7.3.4.2.2. By End User
  • 7.3.5. Spain RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Indication
      • 7.3.5.2.2. By End User

8. Asia-Pacific RNA Targeting Small Molecule Drug Discovery Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)
  • 8.2.2. By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Indication
      • 8.3.1.2.2. By End User
  • 8.3.2. India RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Indication
      • 8.3.2.2.2. By End User
  • 8.3.3. Japan RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Indication
      • 8.3.3.2.2. By End User
  • 8.3.4. South Korea RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Indication
      • 8.3.4.2.2. By End User
  • 8.3.5. Australia RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Indication
      • 8.3.5.2.2. By End User

9. South America RNA Targeting Small Molecule Drug Discovery Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)
  • 9.2.2. By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Indication
      • 9.3.1.2.2. By End User
  • 9.3.2. Argentina RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Indication
      • 9.3.2.2.2. By End User
  • 9.3.3. Colombia RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Indication
      • 9.3.3.2.2. By End User

10. Middle East and Africa RNA Targeting Small Molecule Drug Discovery Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)
  • 10.2.2. By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Indication
      • 10.3.1.2.2. By End User
  • 10.3.2. Saudi Arabia RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Indication
      • 10.3.2.2.2. By End User
  • 10.3.3. UAE RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Indication
      • 10.3.3.2.2. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global RNA Targeting Small Molecule Drug Discovery Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Accent Therapeutics, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Anima Biotech Inc.
• 15.3. Arrakis Therapeutics, Inc.
• 15.4. AstraZeneca Plc
• 15.5. Epics Therapeutics, Inc.
• 15.6. Expansion Therapeutics, Inc.
• 15.7. F.Hoffmann-La Roche AG
• 15.8. H3 Biomedicine Inc.
• 15.9. PTC Therapeutics, Inc.
• 15.10. Ribometrix, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer